ERBB2 and breast cancer: While the interactive effect modeling approach used by PATH requires the use of statistical treatment–subgroup interactions, our causal framework can accommodate more general scenarios, such as making treatment decisions involving HER2-targeted agents for breast cancer (Figure 7A) based on preclinical research.